06 May 2026 Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026 Investors | Therapeutics
21 Apr 2026 Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform Investors | Therapeutics
31 Mar 2026 Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) – a sustained-release pre|CISION® exatecan peptide drug conjugate Investors | Therapeutics
26 Mar 2026 Proposed Placing via an accelerated bookbuild and Subscription to raise approximately £10 million Investors
17 Mar 2026 Avacta Announces Preclinical and Translational Presentations of pre|CISION® Platform Candidates at the 2026 AACR Annual Conference Investors | Therapeutics
16 Mar 2026 Avacta announces opening of Phase 1 trial for second pipeline asset, FAP-Exd (AVA6103) a sustained-release pre|CISION® exatecan peptide-drug conjugate Investors | Therapeutics